California Public Employees Retirement System Increases Holdings in DexCom, Inc. $DXCM

California Public Employees Retirement System lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 21.3% in the first quarter, Holdings Channel reports. The fund owned 637,344 shares of the medical device company’s stock after purchasing an additional 111,931 shares during the quarter. California Public Employees Retirement System’s holdings in DexCom were worth $40,025,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new stake in DexCom during the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom in the 1st quarter worth approximately $25,000. CVA Family Office LLC boosted its holdings in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. MCF Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at approximately $32,000. Finally, ORG Partners LLC increased its position in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 71,750 shares of company stock valued at $5,163,241. Insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of several recent research reports. William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Truist Financial boosted their price objective on shares of DexCom from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Bank of America reduced their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $85.36.

DexCom Trading Down 1.3%

Shares of NASDAQ DXCM opened at $75.69 on Tuesday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The company has a market cap of $29.21 billion, a price-to-earnings ratio of 32.35, a PEG ratio of 1.26 and a beta of 1.45. The business’s 50 day moving average price is $71.48 and its 200-day moving average price is $68.80.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 EPS. On average, sell-side analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.